Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis
Public ClinicalTrials.gov record NCT01639339. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab Plus Standard of Care Versus Placebo Plus Standard of Care in Adult Subjects With Active Lupus Nephritis
Study identification
- NCT ID
- NCT01639339
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Human Genome Sciences Inc., a GSK Company
- Industry
- Enrollment
- 448 participants
Conditions and interventions
Conditions
Interventions
- Placebo plus standard therapy Biological
- Belimumab 10 mg/kg plus standard therapy Biological
- Standard therapy Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 11, 2012
- Primary completion
- Jul 24, 2019
- Completion
- Mar 11, 2020
- Last update posted
- Mar 18, 2021
2012 – 2020
United States locations
- U.S. sites
- 17
- U.S. states
- 9
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | La Palma | California | 90623 | — |
| GSK Investigational Site | San Leandro | California | 94578 | — |
| GSK Investigational Site | Torrance | California | 90502 | — |
| GSK Investigational Site | Gainesville | Florida | 32610 | — |
| GSK Investigational Site | Miami | Florida | 33136 | — |
| GSK Investigational Site | St Louis | Missouri | 63110 | — |
| GSK Investigational Site | Brooklyn | New York | 11203 | — |
| GSK Investigational Site | Great Neck | New York | 11021 | — |
| GSK Investigational Site | Manhasset | New York | 11030 | — |
| GSK Investigational Site | New York | New York | 10016 | — |
| GSK Investigational Site | New York | New York | 10032 | — |
| GSK Investigational Site | Chapel Hill | North Carolina | 27599 | — |
| GSK Investigational Site | Columbus | Ohio | 43203 | — |
| GSK Investigational Site | Bethlehem | Pennsylvania | 18017 | — |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19140 | — |
| GSK Investigational Site | Charleston | South Carolina | 29425 | — |
| GSK Investigational Site | Onalaska | Wisconsin | 54650 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 101 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01639339, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 18, 2021 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01639339 live on ClinicalTrials.gov.